Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of IN-G00002 vs IN-R00002 (Edoxaban) in Healthy Volunteers
NCT06725355Phase 1Active, not recruiting
- Sponsor
- HK inno.N Corporation
- Start
- Aug 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of edoxaban in Atrial fibrillation (AFib) (2 arms), sponsored by HK inno.N Corporation. Primary endpoint: Pharmacokinetic parameters. Started Aug 2024; status: active, not recruiting.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06725355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06725355.